Intravenous @entity1206 as first-line and second-line therapy in XXXX .

@entity1 @entity137 @entity295 @entity0 @entity8253 @entity5 @entity1206 @entity3028
PURPOSE: We evaluated single-agent intravenous (IV) @entity1206 as first- and second-line treatment for @entity0 ( @entity0 ) in @entity1 who were not resistant to @entity8253 . Objective @entity5 response (TR) and @entity137 were assessed. @entity1 AND METHODS: A total of 107 @entity1 were enrolled onto this multicenter, nonrandomized, open-label phase II study. @entity1 were stratified into first- and second-line treatment groups, based on prior treatment history. @entity1206 was initially given at 30 mg/m2/wk, with dose modification for @entity137 as indicated. Therapy was continued until disease progression or severe @entity137 mandated withdrawal or until the @entity1 asked to be removed from the study. RESULTS: The objective response rate for all @entity1 was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line @entity1 and 32% (95% CI, 20% to 47%) for second-line @entity1 . Nine first-line and three second-line @entity1 obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second-line @entity1 were 67 weeks and 62 weeks, respectively. @entity3028 was the predominant dose-limiting @entity137 . Two @entity1 died on study as a result of @entity295 . CONCLUSION: Single-agent @entity1206 is an effective and well-tolerated agent for first- and second-line therapy of @entity0 . The results of this study confirm the findings of similar international trials and suggest @entity1206 should be considered a valid treatment option for @entity1 with @entity0 and a potential component in future combination regimens for this disease.
